Last reviewed · How we verify

NCT07373938

Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus

Recruiting now Last updated 29 January 2026
What this trial tests

trial testing SCORE2 in Type 2 Diabetes Mellitus in 80 participants. Currently enrolling.

Timeline
25 January 2026
Primary endpoint
28 January 2026
2 August 2026

Quick facts

Lead sponsorCardenal Herrera University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment80
Start date25 January 2026
Primary completion28 January 2026
Estimated completion2 August 2026
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Cardenal Herrera University

Who can join

Adults 40 to 69, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to compare carotid intima-media thickness (CIMT) and layer-specific texture characteristics of the carotid wall between individuals with Type 2 diabetes mellitus (T2DM) and normoglycemic controls, to assess the impact of T2DM on these ultrasound variables and evaluate their ability to discriminate between low and high cardiovascular risk at 10 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of SCORE2

Trials testing the same drug.

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

Other Cardenal Herrera University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07373938.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing